MAXCYTE, INC. MXCT

About MAXCYTE, INC. (MXCT): stock profile, AI score and financials

MAXCYTE, INC. (MXCT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MXCT at 13.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,833 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (4.7) and revenue scale (5.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MAXCYTE, INC. reports quarterly revenue of $7.3M, net income of $-8.9M, an operating margin of -140.7%. Top institutional holders of MXCT by reported 13-F value include Capricorn Fund Managers Ltd, Vitruvian Partners LLP, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MXCT trades on the Nasdaq exchange and files with the SEC under CIK 1287098. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MXCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MAXCYTE, INC. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1287098 →